RxDoctor Payments Data

May-Thu Hung, NP

Family · Webster, TXNPI 1760067714

Payments from drug & device makers

$2,368in general payments, 2019–2025

Across 115 payments — averaging $20.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$867
  • Astellas Pharma US Inc$647
  • Axonics, Inc.$222
  • Urovant Sciences Inc$158
  • Pfizer$139
  • 180 Medical, Inc.$116
  • plus $219 from 5 others

What the payments were for

  • Food & beverage$2,26896%
  • Education$1004%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sumitomo Pharma America, Inc.45$867
Astellas Pharma US Inc30$647
Axonics, Inc.9$222
Urovant Sciences Inc8$158
Pfizer7$139
180 Medical, Inc.5$116
Convatec Inc.5$108
Millicent US Inc3$59
Hollister Incorporated1$23
Exact Sciences1$15
Hologic Sales And Service, LLC1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,368 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$38,360
Medicare patients
171
Services billed
707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron145$123,169
MyrbetriqMirabegron108$111,665
Mirabegron ErMirabegron32$27,728
PremarinEstrogens, Conjugated47$20,131
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst218$4,582
Fosfomycin Tromethamine23$3,133
Estradiol44$2,929
Solifenacin Succinate59$2,711
Methenamine Hippurate22$2,398
Cephalexin383$2,221
CefuroximeCefuroxime Axetil105$1,531
Tolterodine Tartrate ErTolterodine Tartrate14$1,505
Oxybutynin Chloride ErOxybutynin Chloride42$1,172
Trimethoprim24$1,109
Ciprofloxacin Hcl114$729

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$867$123,169145 claims
Astellas Pharma US IncMyrbetriq$647$111,665108 claims
PfizerPremarin$139$20,13147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.

Other family in Webster

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →